ProKidney (NASDAQ: PROK)
$1.66
(-9.3%)
-$0.17
Price as of January 8, 2025, 4:00 p.m. ET
ProKidney Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ProKidney Company Info
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.